Simplify Propel Opportunities ETF Rating $23.04 +0.26 (+1.14%) (As of 11/20/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Simplify Propel Opportunities ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.SURI Aggregate RatingModerate Buy 2.77Holdings in SURI have an aggregate rating of Moderate Buy based on 130 analyst ratings issued in the past year covering 18 companies (96.6% of the portfolio).SURI Aggregate Price Target$23.04High Prediction$23.04Average Prediction$23.04Low Prediction$23.04Holdings in SURI have an aggregate price target of $23.04 and a range of $23.04 to $23.04 covering 18 companies (96.6% of the portfolio).SURI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy8 Buy rating(s)Moderate Buy7 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Simplify Propel Opportunities ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 18 SURI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings23.59%APLTApplied Therapeutics$9.39-0.4%4.362 of 5 stars3.17$12.50 33.1%620.59%PAGPPlains GP$19.15+1.8%2.594 of 5 stars2.22$19.88 3.8%9Positive News8.30%PHATPhathom Pharmaceuticals$9.33+6.9%2.3252 of 5 stars2.75$22.50 141.2%47.11%MDGLMadrigal Pharmaceuticals$326.66+3.0%3.784 of 5 stars2.69$347.33 6.3%13Analyst Forecast6.85%AKROAkero Therapeutics$30.98+1.1%4.0631 of 5 stars2.88$46.83 51.2%8Analyst ForecastInsider Trade5.35%TCRXTScan Therapeutics$4.05-1.7%2.9905 of 5 stars3.00$12.00 196.3%55.11%RNAAvidity Biosciences$43.84+0.4%2.4064 of 5 stars3.00$63.22 44.2%9Insider TradeAnalyst Revision4.81%CASHPathward Financial$81.87+3.0%2.8108 of 5 stars2.50$74.50 -9.0%2Short Interest ↓Positive News3.78%ARDXArdelyx$5.20+5.7%3.9209 of 5 stars2.88$10.42 100.3%8Short Interest ↑2.24%ABEOAbeona Therapeutics$5.95+3.5%3.6063 of 5 stars3.00$18.00 202.5%3Analyst Upgrade1.48%SNDXSyndax Pharmaceuticals$15.81-0.9%4.0171 of 5 stars2.91$37.64 138.1%11Analyst ForecastAnalyst Revision1.45%TSATTelesat$11.56+4.8%1.2138 of 5 stars2.00$9.00 -22.1%11.31%KYMRKymera Therapeutics$44.16+0.2%1.4142 of 5 stars2.81$52.13 18.1%16Analyst Forecast1.22%KURAKura Oncology$10.43-34.4%4.0972 of 5 stars3.00$29.43 182.2%10Analyst ForecastNews CoverageGap DownHigh Trading Volume0.96%ATHAAthira Pharma$0.67+4.3%2.8397 of 5 stars2.00$13.83 1,964.7%40.94%ACHVAchieve Life Sciences$4.35+1.2%1.4938 of 5 stars3.33$14.80 240.2%60.91%ZVRAZevra Therapeutics$9.17+2.2%3.4632 of 5 stars3.13$21.00 129.0%8Analyst ForecastAnalyst Revision0.55%CMPSCOMPASS Pathways$4.51-3.2%2.8592 of 5 stars3.00$30.67 580.0%7Short Interest ↓ This page (NYSEARCA:SURI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Simplify Propel Opportunities ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Simplify Propel Opportunities ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SURI Stock Alerts